

Maximizing Global Success

- The strong collaboration between Ipsen and Exelixis began in 2016 to support commercialization and further development of Exelixis' Cabometyx[®] (cabozantinib), a novel small molecule inhibitor of the tyrosine kinases c-Met, VEGFR2, AXL and RET. Ipsen's initial indication focused on advanced renal cell carcinoma (RCC) outside of the U.S. and Japan.
- Today, Cabometyx is approved in 58 countries for RCC, including the E.U. where it is approved in combination with nivolumab as a first line treatment, and in 54 countries for hepatocellular carcinoma (HCC). Studies at Ipsen are ongoing in a form of thyroid cancer and solid tumors. The relationship reflected the companies' shared vision: to maximize the franchise potential and bring cabozantinib to patients and clinicians around the world.
- This partnership exemplifies Ipsen's mission to become a market leader by growing and expanding assets in areas of high unmet need through robust life cycle management, while driving commercial success for both partners and patients.

***“In Ipsen, Exelixis has an ideal partner to maximize the potential for cabozantinib to have a positive impact on the treatment of cancer on a global basis.*”**

While our immediate priority will be on advanced renal cell carcinoma, Exelixis and Ipsen are committed to exploring and potentially developing cabozantinib in a variety of cancer settings.”

***-- Michael M. Morrissey, Ph.D.,
President and Chief Executive Officer,
Exelixis (2016)***